oxybutynin has been researched along with Depressive Disorder, Major in 5 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Efforts to develop existing drugs into user-friendly dosage forms with a number of advantages in major depressive states, including but not limited to: sustained drug release, reduced drug dosing frequency, improved tolerance and adherence, suitability for use in diverse populations and different treatment scenarios, as well as less central nervous system side effects are required." | 2.72 | Transdermal Route: A Viable Option for Systemic Delivery of Antidepressants. ( Khanna, G; Nunez, E; Puri, A; Singh, K; Tijani, AO, 2021) |
| " Patient adherence theoretically could be improved due to ease of use and once-daily dosing when compared to oral counterparts' need for multiple daily doses." | 2.52 | A critical appraisal of the selegiline transdermal system for major depressive disorder. ( Bied, AM; Kim, J; Schwartz, TL, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tijani, AO | 1 |
| Nunez, E | 1 |
| Singh, K | 1 |
| Khanna, G | 1 |
| Puri, A | 1 |
| DelBello, MP | 1 |
| Hochadel, TJ | 1 |
| Portland, KB | 1 |
| Azzaro, AJ | 1 |
| Katic, A | 1 |
| Khan, A | 1 |
| Emslie, G | 1 |
| Nakonezny, PA | 1 |
| Mayes, TL | 1 |
| Byerly, MJ | 1 |
| Emslie, GJ | 1 |
| Bied, AM | 1 |
| Kim, J | 1 |
| Schwartz, TL | 1 |
| Cristancho, MA | 1 |
| Thase, ME | 1 |
3 reviews available for oxybutynin and Depressive Disorder, Major
| Article | Year |
|---|---|
Transdermal Route: A Viable Option for Systemic Delivery of Antidepressants.
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Major; Drug Delivery Systems; | 2021 |
A critical appraisal of the selegiline transdermal system for major depressive disorder.
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Major; Drug Liberation; Human | 2015 |
Critical appraisal of selegiline transdermal system for major depressive disorder.
Topics: Administration, Cutaneous; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selegil | 2016 |
1 trial available for oxybutynin and Depressive Disorder, Major
| Article | Year |
|---|---|
A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
Topics: Administration, Cutaneous; Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dou | 2014 |
1 other study available for oxybutynin and Depressive Disorder, Major
| Article | Year |
|---|---|
Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
Topics: Adolescent; Child; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Neuroprote | 2015 |